SCHEMBL3757741

SCHEMBL3757741

CC(=O)Nc1cn[c]c(-c2ccccc2)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 3/20 0.43
HDAC1 Q13547 2/20 0.43
APOBEC3A P31941 2/20 0.43
APOBEC3G Q9HC16 2/20 0.43
GFER P55789 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC2 Q92769 1/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ADORA3 P0DMS8 4/20 0.41
ADORA1 P30542 3/20 0.41
POLB P06746 1/20 0.40
CYP2C19 P33261 1/20 0.40
NAPRT Q6XQN6 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TSHR P16473 1/20 0.39
ADORA2B P29275 1/20 0.38
ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3764873 0.81 BRD9 (0.47) HDAC1LMNAPOLBNPC1RAB9A
SCHEMBL3757720 0.80 TDO2 (0.34) ALDH1A1HPGDKDM4EPOLBHSD17B10
SCHEMBL3754761 0.79 KDM4E (0.45) ALDH1A1HPGDKDM4EHDAC1APOBEC3A
SCHEMBL3765998 0.77 KEAP1 (0.43) L3MBTL1KMT2A
SCHEMBL3760094 0.73 AXL (0.45) ALDH1A1HPGDKDM4ELMNASMN1; SMN2
SCHEMBL3751948 0.71 SMN1; SMN2 (0.47) ALDH1A1HPGDKDM4ESMN1; SMN2NPC1
SCHEMBL3761781 0.69 ALDH1A1 (0.33) ALDH1A1KDM4ESMN1; SMN2POLBL3MBTL1
SCHEMBL3763849 0.69 MAPT (0.38) ALDH1A1HPGDKDM4ELMNAADORA3
SCHEMBL16719499 0.69 CYP2C19 (0.51) ALDH1A1HPGDKDM4EHDAC1APOBEC3A
SCHEMBL3761589 0.67 ADORA2A (0.35) SMN1; SMN2ADORA2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ALDH1A1 3061/4885HPGD 3366/4885KDM4E 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.